CD59, an essential glycoprotein on cell surfaces, regulates complement-mediated lysis by inhibiting the membrane attack complex (MAC). As a guardian of cellular integrity, sCD59 prevents inflammation and thrombosis by blocking MAC formation. Its ubiquitous presence across mammalian cells underscores its role in immune regulation and T cell activation. CD59 gene mutations lead to deficiency, causing hemolytic anemia and cerebral infarction, highlighting its clinical importance. With levels ranging from 22 to 119 ng/ml in healthy plasma, sCD59 emerges as a crucial biomarker for immune health, offering therapeutic potential for complement-related disorders.
Application
The sCD59 ELISA kit is to be used for the in vitro quantitative determination of human sCD59 in plasma.
Principle
The sCD59 ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 3½ hours. The efficient format of a plate with twelve disposable 8-well strips allows free choice of batch size for the assay. Samples and standards are incubated in microtiter wells coated with antibodies recognizing human sCD59. Biotinylated tracer antibody will bind to the captured human sCD59. Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody. Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB). The enzyme reaction is stopped by the addition of oxalic acid. The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the human sCD59 standards (log). The human sCD59 concentration of samples, which are run concurrently with the standards, can be determined from the standard curve.